Selank

Selank has been given to people, but the human record behind it is one small Russian trial, and that trial never tested Selank on its own. A Moscow group gave 40 patients with anxiety disorders Selank alongside the benzodiazepine phenazepam and compared them with 30 patients on phenazepam alone. Everything else cited for it comes from rats or from rat brain tissue in a test tube.

The trial reported that the phenazepam response showed up sooner on the Hamilton scale and that several familiar benzodiazepine side effects, such as sedation and memory complaints, were milder when Selank was added. The published summary gives no effect sizes, no placebo arm and no blinding details, and every paper behind the compound traces back to the same Moscow research institute that designed it.

Selank is a synthetic seven amino acid peptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. The first four residues are tuftsin, a short fragment of the heavy chain of human immunoglobulin G. Its designers added Pro-Gly-Pro to the end to make the molecule more resistant to breakdown and longer acting.

It was created at the Institute of Molecular Genetics of the Russian Academy of Sciences together with the V.V. Zakusov Research Institute of Pharmacology. The FDA lists it under the name Selank acetate (TP-7). It is not an approved drug in the United States.

A Proposed Link to the GABA System

Benzodiazepines such as diazepam calm the nervous system by making GABA receptors respond more strongly to GABA, the brain's main inhibitory signal. The working idea behind Selank is that it nudges the same system by a different route.

The most direct test used radioligand binding on rat brain membranes. Selank changed how much labelled GABA bound to its receptors, behaving like a positive allosteric modulator, and it blocked the modulating effect of diazepam and olanzapine on that binding. The authors concluded that its binding site is probably not the same as the benzodiazepine site, though the two may partly overlap.

What the Gene Expression Work Adds

In a second study, 30 male rats received Selank, GABA or water, and researchers measured 84 neurotransmission genes in the frontal cortex. Selank shifted the activity of 29 of those genes at one hour and 17 at three hours, and its early pattern correlated with the pattern GABA produced. That is a fingerprint of overlapping biology in rat brain tissue. It does not show what the peptide does to anxiety, mood or thinking in a person.

Treating an add-on result as a standalone one. The only human trial gave Selank on top of phenazepam. It shows what happened to people already taking a benzodiazepine, not what Selank does by itself, and it cannot be read as evidence that Selank replaces one.

Reading fewer side effects as a calming effect. The clearest reported finding is that phenazepam's side effects were milder in the combined group. That is a statement about tolerability of another drug, measured without a placebo arm, and it is a different claim from Selank relieving anxiety.

Ignoring who produced the evidence. N.F. Myasoedov, of the institute that designed Selank, is an author on every one of the four studies, and all three laboratory papers come from that institute. Nobody outside that circle has replicated these findings in the sources cited here.

Turning rat gene changes into human outcomes. Shifts in frontal cortex mRNA an hour after a single exposure in rats say nothing about focus, mood or stress tolerance in a person.

Assuming a sport clearance that does not exist. Selank is not named on the WADA Prohibited List, but that does not settle whether it is permitted. Its status there is unresolved.

The safety record in people is the 40 patients in the one combined trial, who were assessed with the UKU side effect scale. The published abstract describes fewer phenazepam side effects in that group and reports no Selank-specific adverse events, but it does not give rates, treatment length or follow-up beyond the tranquilizer withdrawal period. Long-term safety in humans has not been studied in the sources cited.

FDA status. Selank is not approved by the FDA and currently sits on neither FDA compounding category list. Selank acetate dropped off Category 2 on or about 22 April 2026 only because whoever nominated it withdrew; FDA never closed out its safety concerns about the peptide, and they are still on the public record. It was not on the agenda of the July 2026 Pharmacy Compounding Advisory Committee meeting.

WADA status. Unknown. Selank is not named on the Prohibited List. Whether Selank falls under S0, the class for substances with no current human-use approval anywhere, depends on whether some health authority outside the United States has approved it, and no primary registry consulted could confirm that either way.

Selank draws attention because it promises a benzodiazepine-like calm without the sedation, memory fog and dependence that make those drugs hard to live with. The evidence gives that idea a starting point and no more.

What has been shown: in rat brain tissue Selank interacts with GABA receptor binding and shifts expression of GABA-related genes, in stressed rats it combined with diazepam to hold anxiety scores at baseline, and in 70 Russian patients adding it to phenazepam was associated with an earlier response and milder side effects.

What has not been shown: that Selank alone reduces anxiety in people, how large any effect is, whether it holds up against placebo, or whether a research group with no tie to its developers would see the same thing. Those are the questions that would move it out of its current tier, and none of the cited sources answers them.

Not a proven treatment for anxiety. The single human trial tested it only as an add-on to phenazepam, without a placebo group, so its effect on anxiety by itself in people is unmeasured.

Not an approved medicine in the United States. The FDA has not approved it, and it currently appears on neither FDA compounding category list after its nominators withdrew.

Not independently confirmed. Every cited study involves the institute that created it, and outside replication is missing from the record.

Not cleared for tested sport. It is absent from the WADA Prohibited List by name, and whether the non-approved substances class captures it remains unresolved.

I find Selank genuinely interesting, mostly because the question it raises is a good one: can you get some of what a benzodiazepine does without the parts that make benzodiazepines dangerous to rely on?

The honest answer is that nobody has tested that properly. The human evidence is one trial of 70 people where Selank was added to a benzodiazepine rather than given instead of one, and the summary I can read reports direction without size. The rat work is coherent and points the same way, but it all comes from one institute, and coherent is not the same as confirmed.

So I hold it in the middle. I will not dismiss it, and I will not let a milder side effect profile in a small add-on trial get repackaged as a calm pill. If someone is dealing with anxiety, the treatments with real trial records behind them are where a clinician will start, and that is the right place to start.